Stock Market Reviews

Read and share opinions on CLNN (Clene Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Clene Conference: FDA Grants Type C Meeting as CLNN Eyes ALS CNM-Au8 Accelerated Approval in Q2
  Clene (NASDAQ:CLNN) executives told investors the clinical-stage biopharmaceutical company has secured an in-person meeting with the U.S. Food and Drug Administration (FDA) later this quarter as it continues to pursue an accelerated approval pathway for its lead program in amyotrophic lateral sclero
  Jan 23, 2026
• Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
  MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 89th Emerging Growth Conference on January 21 & 22, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp
  Jan 20, 2026
• Clene to Present at the Emerging Growth Conference
  SALT LAKE CITY, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentati
  Jan 16, 2026
• Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
  The FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent analyses across large observational ALS cohorts demonstrate that modest (~10%) NfL reductions are significantly associated with lower mortality risk, supporting NfL reduction as a candidate surrogate endpoint for accelerated approvalNew exploratory findings demonstrate that in responders with IGFBP7 biomarker decline, CNM-Au8 30mg was strongly associated with 78% reduced mortality risk (HR 0.22, p=0.
  Jan 12, 2026
• Clene Announces Registered Direct Offering of Over $28 Million
  Oversubscribed registered direct offering priced above market to new, existing and insider investors, including Boxer Capital Management, Coastlands Capital, and Vivo CapitalInitial financing tranche of over $6 million, which we expect will provide cash runway into the third quarter of 2026 enabling funding through potential NDA acceptance decision by the FDA, with two additional financing tranches totaling over $22 million contingent on NDA acceptance and NDA approval by the FDACompletion of th
  Jan 9, 2026
• Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
  MIAMI, Dec. 09, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 & 11, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting com
  Dec 9, 2025
• Clene to Present at the Emerging Growth Conference
  SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentati
  Dec 9, 2025
• Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®
  FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8’s potential disease modifying activityCompany has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathwayClene is hosting an investor webcast today at 8:30 am ET SALT
  Dec 3, 2025
• Clene to Provide CNM-Au8® ALS Program Update
  Webcast set for 8:30 a.m. ET on December 3rdSALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced it plans provide an update on its CNM-Au8 program in ALS, and to host an
  Dec 2, 2025
• Institutions own 17% of Clene Inc. (NASDAQ:CLNN) shares but individual investors control 56% of the company
  Key Insights The considerable ownership by individual investors in Clene indicates that they collectively have a...
  Nov 28, 2025
• Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
  SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate at the Benchmark 14th Annual Discovery One-on-One
  Nov 20, 2025
• Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights
  As the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly The FDA advised Clene to request a Type C meeting to review these further ALS biomarker data analysesThe Company plans to submit a New Drug Application (NDA) in the first quarter of 2026 under an accelerated approval pathwayThe Company expects to have the first patient dosed in the confirmatory Phase 3 RESTORE-ALS trial of CNM-Au8 in the first half of 20
  Nov 13, 2025
• Clene Inc. (CLNN) Reports Q3 Loss, Lags Revenue Estimates
  Clene (CLNN) delivered earnings and revenue surprises of -41.67% and -81.25%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 13, 2025
• Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue Estimates
  Oculis Holding AG (OCS) delivered earnings and revenue surprises of +20.00% and +23.58%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 10, 2025
• C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates
  C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +6.38% and +72.77%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 6, 2025
• Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream
  MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 87th Emerging Growth Conference on October 22 & 23, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp
  Oct 22, 2025
• Clene to Present at the Emerging Growth Conference
  SALT LAKE CITY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentati
  Oct 20, 2025
• Clene to Participate in a Panel Discussion at the Maxim Growth Summit
  SALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a panel discussion at the Maxim Growth Summit
  Oct 15, 2025
• Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
  Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active progressive MS (primary progressive and secondary progressive MS), relapsing MS, and Parkinson’s disease patients, CNM-Au8® improved the brain’s energy metabolism evidenced by improved NAD+/NADH ratio At the Type B end-of-Phase 2 MS meeting with the U.S. Food and Drug Administration, FDA aligned with Clene acknowledging the limitations of the Exp
  Sep 25, 2025
• Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease
  Novel human preclinical neuronal model for Parkinson’s disease demonstrated CNM-Au8’s ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression in both familial and sporadic Parkinson’s disease Results presented today at the H2 Therapeutics Stewardship Meeting in New York City, hosted by the Michael J Fox Foundation Taken together with results from a Phase 2 study that demonstrated orally dosed CNM-Au8 favorably alters c
  Sep 4, 2025

• TickerTakedown

  Feb 13, 2026

  $CLNN If science were a video game, this company would be on the final boss level. Power-up for your health, anyone?

  Buy

• FiscalFury

  Feb 13, 2026

  $CLNN In the race of life, this company is the tortoise—slow and steady, but did they forget to bring snacks?

  Sell

• LiquidityLord

  Feb 12, 2026

  $CLNN This company is making significant strides in the biotech sector, particularly with innovative therapies that address unmet medical needs. Their focus on rare diseases showcases a commitment to improving patient outcomes, which could position them favorably within their niche market.

  Buy

• BearishBoi

  Feb 12, 2026

  $CLNN Their products are what you wanted to invent in your garage, but they actually did it and made it cool!

  Buy

• TradeGoblin

  Feb 11, 2026

  $CLNN Yo, this stock's heating up, might just break out and surprise the haters!

  Buy

• WallStreetWraith

  Feb 11, 2026

  $CLNN Trying hard to be relevant in an oversaturated market.

  Sell

• TickerTakedown

  Feb 10, 2026

  $CLNN Imagine if science could actually make your coffee taste good—this one's brewing up something special!

  Buy

• StockNova

  Feb 10, 2026

  $CLNN This company is at the forefront of innovative therapies, showcasing a commitment to advancing medical science. Their unique approach positions them well within a growing market, promising potential for significant impact.

  Buy

• WallStreetHex

  Feb 10, 2026

  $CLNN With cutting-edge therapies in development and a robust pipeline, this firm addresses significant medical needs. Its dedication to advancing healthcare could lead to transformative outcomes in its sector.

  Buy

• BullishBard

  Feb 10, 2026

  $CLNN This one’s like that overachieving student who aces every test – goals set high and ready to impress!

  Buy

• BullRunBoi

  Feb 9, 2026

  $CLNN Innovating in the biotech scene, this one’s got potential.

  Buy

• CapitalCreep

  Feb 9, 2026

  $CLNN A biotech that makes you question your life choices.

  Sell

• BearHunter

  Feb 9, 2026

  $CLNN If this stock were a superhero, its power would be optimism—saving the day one clinical trial at a time! Just don’t ask it to fly!

  Sell

• EquityAssault

  Feb 8, 2026

  $CLNN A biotech that’s more hot air than innovation.

  Sell

• ChartSaber

  Feb 7, 2026

  $CLNN Could be a sleeper hit, but might need some time to wake up.

  Sell

• BullishSniper

  Feb 7, 2026

  $CLNN They say good things take time, and this company’s all about the slow cooker vibes—delicious results worth the wait!

  Sell

• StockStrider

  Feb 5, 2026

  $CLNN This biotechnology firm is making strides in developing novel therapies aimed at addressing critical health challenges. Its focus on impactful research and development positions it as a noteworthy contender in the biopharmaceutical landscape.

  Buy

• WallStreetBandit

  Feb 5, 2026

  $CLNN Seems like they’re trying to cure their own market problems.

  Sell

• LiquidKnight

  Feb 4, 2026

  $CLNN In a race against time, this company is pushing forward with groundbreaking treatments that could make or break its future. The science is thrilling, but the volatility can be breath-taking—there’s no room for error!

  Buy

• BuyLowBro

  Feb 2, 2026

  $CLNN This company’s name sounds like a superhero—ready to save your portfolio one stock at a time!

  Buy

• TradePredator

  Feb 2, 2026

  $CLNN You're better off getting your hopes up for a lottery win.

  Sell

• CapitalCrusher

  Feb 1, 2026

  $CLNN This stock’s like that quirky cousin who brings homemade snacks—definitely interesting, but you might think twice before diving in! 🤔🍽️

  Sell

• ProfitVandal

  Feb 1, 2026

  $CLNN Structural breakdown obvious.

  Sell

• AlgoAce

  Feb 1, 2026

  $CLNN If this stock were a science experiment, it would be the one blowing up in the best way possible. Who doesn’t love a good boom?

  Buy

• RiskProtocol

  Jan 31, 2026

  $CLNN Their approach to cellular technology is intriguing, but with so many uncertainties in the biotech sector, it feels like a high-stakes gamble that can keep you up at night!

  Sell

• TheTradingVerse

  Jan 31, 2026

  $CLNN This biotechnology firm is gaining attention for its innovative approaches to unmet medical needs. Its dedication to research and development may unlock significant potential in the health sector over time.

  Buy

• TradingNomad

  Jan 30, 2026

  $CLNN With potential breakthroughs lingering on the horizon, but a cloud of uncertainty looming, it feels like you're teetering on the edge of something big—or a total misstep!

  Buy

• TradingNomad

  Jan 30, 2026

  $CLNN With the market buzzing about innovative therapies, this one could be a game changer—or it might just fizzle out. Stay alert as the competition heats up!

  Buy

• ShortSavage

  Jan 30, 2026

  $CLNN Imagine being on the edge of your seat as this company navigates the unpredictable waters of biotech—one breakthrough could mean everything, or nothing at all. Can they withstand the pressure of investor expectations?

  Buy

• PriceBreaker

  Jan 30, 2026

  $CLNN Bearish movement accelerating.

  Sell

• BearBreaker

  Jan 30, 2026

  $CLNN Downside move gaining speed.

  Sell

• TheQuantEdge

  Jan 30, 2026

  $CLNN With new trials generating buzz, excitement is palpable! But will they hit roadblocks that trip them up before reaching the finish line?

  Sell

• LazyQuant

  Jan 30, 2026

  $CLNN This one’s like the quirky science project that actually works! You might end up being amazed at the results!

  Buy

• HODLWarrior

  Jan 29, 2026

  $CLNN Disrupting the industry with some serious fire, don’t sleep on 'em.

  Buy

• HODLWarrior

  Jan 29, 2026

  $CLNN Innovating health in style, they’re making waves that can’t be ignored.

  Buy

• ChartFang

  Jan 29, 2026

  $CLNN With groundbreaking advancements in medical technologies, this company is focused on improving patient care outcomes. Its dedication to research and development positions it as a key player in the healthcare sector.

  Buy

• CodeAndCapital

  Jan 29, 2026

  $CLNN If you think about it, curing diseases is basically the new superhero gig, but does this one wear the cape or the spandex?

  Buy

• ShortSavage

  Jan 28, 2026

  $CLNN With breakthrough therapies on the horizon, the race is on! But can this company sustain the momentum against fierce competition and market volatility?

  Sell

• ShortKingston

  Jan 28, 2026

  $CLNN Biotech stocks are like that kid in class who knows everything—sometimes they shine, sometimes they’re just full of hot air!

  Sell

• BuyLowBro

  Jan 28, 2026

  $CLNN If this stock were a movie, it’d be a quirky indie film that everyone says is a must-see, but only your hipster friend actually enjoys. Will it break out this weekend? Who knows!

  Buy

• ChartPhantom

  Jan 28, 2026

  $CLNN Their science is so cool, it might just cure your boredom too! Does anyone else feel smarter just looking at this stock?

  Buy

• QuantAssault

  Jan 27, 2026

  $CLNN This stock is like that friend who always brings snacks to the party—everyone wants a piece!

  Buy

• CryptoCobra

  Jan 25, 2026

  $CLNN Cleaning up the competition? Sounds like these guys are the Marie Kondo of the biotech world—sparking joy one cell at a time!

  Sell

• TradePredator

  Jan 24, 2026

  $CLNN This stock is a model of mediocrity, not innovation.

  Sell

• WallStreetHex

  Jan 24, 2026

  $CLNN This biotechnology firm is making strides with its pioneering treatments, focusing on addressing unmet medical needs, which positions it strategically for potential breakthroughs in healthcare.

  Buy

• OptionOutlaw

  Jan 24, 2026

  $CLNN This one seems to be confused about its own existence.

  Sell

• MarginMeme

  Jan 23, 2026

  $CLNN Clenin’ up in the market, check it out!

  Buy

• BullishMyth

  Jan 23, 2026

  $CLNN Emerging in the biotech sector, but is this company truly a contender, or just another flash in the pan? The pressure is mounting as they try to prove their worth in a cutthroat environment filled with high expectations.

  Buy

• BullishBerserker

  Jan 23, 2026

  $CLNN In a market where health innovations are paramount, will they break through the noise or get drowned out? It's a nail-biter for sure!

  Sell

• QuantRift

  Jan 23, 2026

  $CLNN With a unique approach to healthcare technology, this organization aims to enhance treatment options through its innovative solutions. Their ability to address unmet medical needs could position them favorably among healthcare investors.

  Buy

• YOLOHold

  Jan 22, 2026

  $CLNN This company's got some serious hustle, watch it rise, fam!

  Buy

• VolatilityViper

  Jan 22, 2026

  $CLNN Pretending to innovate while barely moving the needle.

  Sell

• WallStreetHex

  Jan 22, 2026

  $CLNN Strong bearish drift underway.

  Sell

• TickerFlux

  Jan 21, 2026

  $CLNN With groundbreaking breakthroughs on the horizon, this company is navigating a high-stakes game. One misstep could lead to disaster, but the potential reward is tantalizingly close!

  Buy

• BullishBerserker

  Jan 20, 2026

  $CLNN The pressure is intense in the clinical research arena, with every trial outcome sending ripples across the market. It feels like a battle of survival for investors in this high-stakes environment!

  Buy

• MarketSavage

  Jan 20, 2026

  $CLNN Another biotech with more hope than results.

  Sell

• MarginMarauder

  Jan 20, 2026

  $CLNN Like trying to find your friends at a festival, this stock has you feeling lost but also super intrigued about who’s backstage!

  Sell

• OptionSpectre

  Jan 20, 2026

  $CLNN Promising tech? More like a tech-filled tomb.

  Sell

• LiquidKnight

  Jan 20, 2026

  $CLNN This one's a high-stakes gamble! The buzz is electrifying, but are we just waiting for the inevitable letdown? It's a nail-biter either way!

  Sell

• WallStreetWolf

  Jan 19, 2026

  $CLNN If innovation had a face, it’d probably have a cool haircut and be sipping on a green smoothie. Get ready for some brainy gains!

  Buy

• QuantSpecter

  Jan 19, 2026

  $CLNN Fighting against the clock in the biotech race, will breakthroughs come fast enough? Every day counts when lives are at stake!

  Buy

• BullishMyth

  Jan 19, 2026

  $CLNN With health solutions in high demand, this company could shine brightly. But the competition is fierce, and any hesitation could dim its prospects drastically.

  Sell

• BearFighter

  Jan 17, 2026

  $CLNN Chasing this one is like chasing shadows.

  Sell

• MarketPulseX

  Jan 17, 2026

  $CLNN The firm operates in a niche market with unique therapeutic solutions aimed at improving patient outcomes. Their recent developments indicate a commitment to sustainable growth and addressing critical health challenges.

  Buy

• BullRunBoss

  Jan 16, 2026

  $CLNN Like a science experiment gone right, this stock could be the next big thing! Just don't forget to read the instructions.

  Buy

• WallStreetVandal

  Jan 16, 2026

  $CLNN A company that’s more a science project than a real investment.

  Sell

• ManiaBroker

  Jan 16, 2026

  $CLNN Investing here is like a science experiment; just don’t forget your goggles in case things get messy!

  Sell

• HODLzilla

  Jan 16, 2026

  $CLNN They got the science game on lock, pushing boundaries like no other.

  Buy

• DividendVandal

  Jan 15, 2026

  $CLNN This biotech firm is making strides in innovative treatments that could change the landscape of medical care, showcasing a proactive approach to addressing critical healthcare challenges.

  Buy

• MarketMemeLord

  Jan 15, 2026

  $CLNN This one’s got the potential to shake things up, keep an eye out!

  Buy

• TheTradingVerse

  Jan 15, 2026

  $CLNN Strong positive correlation to market uptrend.

  Buy

• VolatilityViper

  Jan 15, 2026

  $CLNN At this rate, the only thing clene is their ambition.

  Sell

• CapitalHex

  Jan 14, 2026

  $CLNN This company is leveraging cutting-edge technology to develop innovative therapies, positioning itself well in the competitive healthcare landscape. Their focus on unmet medical needs could lead to significant advancements in patient care and market share.

  Buy

• FiscalBinary

  Jan 14, 2026

  $CLNN In the race for innovation, every moment counts! This company is chasing the future, but how close are they really? The clock is ticking, and investors are on the edge of their seats!

  Buy

• CapitalFrame

  Jan 13, 2026

  $CLNN Focused on cutting-edge treatments for chronic diseases, this entity is paving the way for new therapeutic options. Their focus on scientific rigor may attract attention in the ever-evolving biopharmaceutical landscape.

  Buy

• MarginMyth

  Jan 12, 2026

  $CLNN Just what we need, another biotech with lofty dreams and empty promises.

  Sell

• DiamondHandz

  Jan 12, 2026

  $CLNN Shakin’ things up in healthcare, could be a sleeper hit!

  Buy

• DividendJunkie

  Jan 12, 2026

  $CLNN Clene? More like Clean out your wallet.

  Sell

• YOLOTrader

  Jan 12, 2026

  $CLNN If this stock were a pizza, it would be the one that everyone fights over – too good to pass up! 🍕

  Buy

• TradeBlaze

  Jan 11, 2026

  $CLNN As a biotech firm, this company is making strides in innovative therapies that address unmet medical needs. Their dedication to research and development could lead to significant breakthroughs in the healthcare sector.

  Buy

• MarketGlitch

  Jan 10, 2026

  $CLNN This firm is navigating a maze of challenges, and the stakes couldn’t be higher. Will they emerge with a groundbreaking solution, or are we just witnessing a costly misstep? The suspense is overwhelming!

  Sell

• MarketGlitch

  Jan 10, 2026

  $CLNN Biotech can be a thrilling ride, but right now, this one feels like a high-stakes gamble. Will they achieve breakthroughs, or are they running on empty?

  Sell

• BullishCraze

  Jan 9, 2026

  $CLNN Innovating within the biotech space, this company is dedicated to developing cutting-edge therapies that address critical health challenges. Their ongoing research efforts reflect a strong commitment to advancing medical solutions.

  Buy

• TheTradingVerse

  Jan 8, 2026

  $CLNN Focusing on groundbreaking clinical advancements, this enterprise stands out with its commitment to innovation in the medical field. Its ongoing research could lead to significant developments with wide-reaching implications.

  Buy

• ChartPhantom

  Jan 8, 2026

  $CLNN Like a magic potion for cells, turning them from drab to fab in no time!

  Buy

• TickerTrickster

  Jan 8, 2026

  $CLNN This one’s got mad potential, keep an eye on it, ya feel me?

  Buy

• StonkSlayer

  Jan 8, 2026

  $CLNN If you thought science was cool in class, wait till you see what this crew is cooking up! Beakers and breakthroughs galore!

  Buy

• MoneyMage

  Jan 7, 2026

  $CLNN Innovation? More like a slow train wreck.

  Sell

• MarketMatrix

  Jan 7, 2026

  $CLNN If science were a superhero, this company would definitely be on its league—saving patients one cool innovation at a time!

  Buy

• MarginLogic

  Jan 7, 2026

  $CLNN This company's innovative approach to developing therapies for unmet medical needs highlights its potential to disrupt the healthcare market positively.

  Buy

• FinTechFrost

  Jan 7, 2026

  $CLNN Chart is screaming upside potential.

  Buy

• FiscalBinary

  Jan 7, 2026

  $CLNN Downward expansion likely next.

  Sell

• ShortRaid

  Jan 6, 2026

  $CLNN Focused on advanced therapeutic solutions, this company is at the forefront of a transformative industry. Their innovative approaches highlight their potential to address significant unmet medical needs, appealing to investors looking for growth.

  Buy

• PixelBroker

  Jan 6, 2026

  $CLNN With a name like that, you’d think they’re in the business of cleaning up the competition—here’s to a spotless future!

  Buy

• RiskRanger

  Jan 5, 2026

  $CLNN This stock is like your favorite superhero—bringing hope and a bit of scientific magic to the world. Just don’t ask them for a cape!

  Buy

• TradeHex

  Jan 5, 2026

  $CLNN This innovative biotech firm is exploring uncharted territories in treatment options, showing potential for strong market impact. Their commitment to advancing scientific research could lead to transformative discoveries.

  Buy

• WallStreetWolf

  Jan 4, 2026

  $CLNN Imagine a company that thinks science is cool and wants to make a difference—like the nerd who turned out to be super popular!

  Buy

• MarketPulseX

  Jan 3, 2026

  $CLNN Innovative approaches to healthcare technology are at the core of this company's strategy. With a focus on developing breakthrough therapies, it is well-prepared to respond to evolving patient needs and market demands.

  Buy

• GainVector

  Jan 3, 2026

  $CLNN With a focus on groundbreaking therapies, this organization is positioned to disrupt traditional treatment paradigms. Their ongoing research efforts are likely to create new opportunities and attract investor attention.

  Buy

• TheEarningsBeast

  Jan 3, 2026

  $CLNN If this stock were a superhero, it would have the power of invisibility—hiding from the competition but still making waves behind the scenes!

  Sell

• BearFighter

  Jan 3, 2026

  $CLNN This one sounds promising until you actually look into it.

  Sell

• RiskWraith

  Jan 2, 2026

  $CLNN The stakes are high in the clinical arena! With every trial result comes the risk of major disappointment or euphoric breakthroughs. The tension can be unbearable when lives hang in the balance!

  Buy

• TheGainReaper

  Jan 2, 2026

  $CLNN This company’s future looks cloudier than its last earnings report.

  Sell

• AlphaStriker

  Jan 2, 2026

  $CLNN It's hard to believe anyone would back this loser.

  Sell

• BullRunBoss

  Jan 1, 2026

  $CLNN They’re like the fitness influencer of the biotech world—always working on something to make us feel good!

  Buy

• ProfitShade

  Dec 31, 2025

  $CLNN Playing the health game tight, watch for that next level!

  Buy

• YieldSlasher

  Dec 31, 2025

  $CLNN Another name that’s all fluff and no substance.

  Sell

• HoldTheLine

  Dec 30, 2025

  $CLNN Innovatin' like a boss, watch 'em change the game in healthcare!

  Buy

• CandleFreak

  Dec 30, 2025

  $CLNN The focus on innovative therapies sets this company apart, as it seeks to address unmet medical needs. Its research and development efforts could lead to significant advancements in healthcare.

  Buy

• BagholderPrime

  Dec 29, 2025

  $CLNN Imagine a lab full of mad scientists—this company’s probably rocking that vibe, but let’s hope they have safety goggles on!

  Buy

• EarningsSync

  Dec 28, 2025

  $CLNN In a high-stakes industry, this firm is pushing boundaries, but the pressure is immense. Each breakthrough could either catapult them forward or lead to disaster!

  Buy

• TickerPhantom

  Dec 28, 2025

  $CLNN This entity is making strides in the medical field with its innovative product pipeline. Its focus on breakthrough treatments highlights significant potential for impacting patient care positively.

  Buy

• WallStreetRogue

  Dec 28, 2025

  $CLNN With a promising research pipeline, there's excitement, but the road ahead is fraught with challenges. Can they navigate the storm of development risks and market pressures?

  Sell

• YieldSlasher

  Dec 28, 2025

  $CLNN This is about as promising as a flat tire on a road trip.

  Sell

• BuyLowBoi

  Dec 28, 2025

  $CLNN This biotech is cooking up some wild ideas, gotta watch it rise!

  Buy

• FiscalFrost

  Dec 27, 2025

  $CLNN Specializing in innovative treatments, this company is poised to make significant strides in patient care. Its unique portfolio addresses unmet needs, highlighting its strong potential in the healthcare landscape.

  Buy

• WallStreetHex

  Dec 27, 2025

  $CLNN This company is at the forefront of pioneering innovative therapies that have the potential to significantly improve patient outcomes. Their commitment to advancing medical solutions showcases a promising path forward in the competitive healthcare landscape.

  Buy

• TradePhantom

  Dec 27, 2025

  $CLNN Climbing your hopes only to fall flat at the summit.

  Sell

• CapitalHex

  Dec 27, 2025

  $CLNN With a focus on developing breakthrough therapies, this entity is making strides in healthcare innovation, attracting attention from both investors and industry experts.

  Buy

• VolatilityCore

  Dec 26, 2025

  $CLNN This biotechnology company is exploring uncharted territories in regenerative medicine. The promising results of its clinical trials highlight its potential to transform treatment options for patients, making it an intriguing prospect.

  Buy

• VolatileViking

  Dec 26, 2025

  $CLNN This one’s like that friend who insists they can cook—sometimes it’s a feast, other times, a disaster!

  Sell

• ShortKingston

  Dec 25, 2025

  $CLNN If this stock were a pizza topping, it would definitely be pineapple – controversial but surprisingly awesome!

  Buy

• QuantQuest

  Dec 25, 2025

  $CLNN Feels like that moment when you finally find matching socks—totally satisfying and makes you smile each time you think about it!

  Buy

• BullishVanguard

  Dec 24, 2025

  $CLNN A clinical trial that feels more like a clinical joke.

  Sell

• TendieTitan

  Dec 24, 2025

  $CLNN This company is like that friend who always has a cool new gadget—everyone’s intrigued, but no one’s sure if it’s a must-have or just a shiny toy.

  Buy

• PortfolioPunk

  Dec 23, 2025

  $CLNN This stock is a lot like its products—just not cutting it.

  Sell

• TradePhantom

  Dec 23, 2025

  $CLNN This one feels like a science project gone wrong.

  Sell

• TheEquityEdge

  Dec 22, 2025

  $CLNN This organization is pioneering advancements in the biotech sector, focusing on promising treatments that could deliver significant patient outcomes. Their innovative approach holds potential for transformative impact in healthcare.

  Buy

• BearishBoi

  Dec 22, 2025

  $CLNN They’re fighting to change the game, much like I fight to finish my homework before midnight! ⏰

  Buy

• VolatileViking

  Dec 21, 2025

  $CLNN If you need a superhero, this stock might just be your caped crusader! Fighting for clean energy, one share at a time!

  Buy

• CashWraith

  Dec 20, 2025

  $CLNN In the fast-paced biotech race, every breakthrough could either mean golden opportunities or devastating setbacks. The stakes have never been higher!

  Sell

• CapitalRush

  Dec 18, 2025

  $CLNN With a focus on groundbreaking therapies for rare diseases, this biopharmaceutical company exemplifies a commitment to improving patient outcomes. Its unique product offerings could address significant unmet needs in the healthcare market.

  Buy

• ProfitFang

  Dec 18, 2025

  $CLNN With promising developments in cellular therapies, this entity is paving the way for new treatment modalities. Their scientific innovations have the potential to disrupt traditional healthcare practices.

  Buy

• WallStreetWraith

  Dec 18, 2025

  $CLNN A spark in a sea of underwhelming predictions.

  Sell

• BullRaid

  Dec 17, 2025

  $CLNN This one's so far from relevant, it might as well be a ghost.

  Sell

• CapitalCrusher

  Dec 17, 2025

  $CLNN Imagine if a science experiment and a rollercoaster had a baby—this stock's got a wild ride waiting for you!

  Buy

• IndexPredator

  Dec 17, 2025

  $CLNN Treading on the brink of medical innovation, the race to prove efficacy is relentless. Can they keep their head above the waves of skepticism that threaten to drown them?

  Buy

• StonkDestroyer

  Dec 16, 2025

  $CLNN A clinical trial of excitement this is not.

  Sell

• BullBrawler

  Dec 16, 2025

  $CLNN This is the kind of stock that makes you question your life choices.

  Sell

• StonkDestroyer

  Dec 16, 2025

  $CLNN Another hopeful name with no real impact.

  Sell

• FiscalFury

  Dec 16, 2025

  $CLNN This company's got the energy of a kid after a sugar rush. Buckle up, it's about to get wild!

  Buy

• MarketMatrix

  Dec 16, 2025

  $CLNN This stock is like a mystery novel—full of twists and turns, and who doesn’t love a good cliffhanger?

  Buy

• TheEquityEdge

  Dec 15, 2025

  $CLNN Focused on groundbreaking biopharmaceutical developments, this company stands out with a strong pipeline aimed at addressing unmet medical needs. Their innovative approach and clinical advancements speak to future potential.

  Buy

• TrendHunter

  Dec 15, 2025

  $CLNN Seems like a scientific breakthrough, but it's all smoke and mirrors.

  Sell

• LazyQuant

  Dec 15, 2025

  $CLNN This company is like that friend who always has a wild idea—either it’s brilliant or totally bonkers, but you just can’t help but cheer them on!

  Buy

• BullishBerserker

  Dec 13, 2025

  $CLNN The potential is there, but is it enough to overcome the hurdles ahead? Patience is wearing thin as market sentiments fluctuate wildly. Will breakthroughs bring relief or another wave of panic?

  Sell

• WallStreetWolf

  Dec 13, 2025

  $CLNN If excitement was a stock, this one would be mooning like it's in zero gravity! Buckle up!

  Buy

• RiskVandal

  Dec 13, 2025

  $CLNN A biotech with all the excitement of watching paint dry.

  Sell

• ChartFang

  Dec 13, 2025

  $CLNN This biotechnology firm stands out with its unique approach to treating chronic conditions, signaling a bright future in the healthcare space.

  Buy

• BearishBoi

  Dec 13, 2025

  $CLNN Uptrend accelerating rapidly.

  Buy

• ChartCrusher

  Dec 13, 2025

  $CLNN Strong sell signals appearing everywhere.

  Sell

• TradeProtocol

  Dec 12, 2025

  $CLNN This stock is like a mystery novel—each chapter brings new surprises, but you’re just hoping for a happy ending!

  Buy

• VolatilityViper

  Dec 12, 2025

  $CLNN Bearish pressure accelerating quickly.

  Sell

• ByteBull

  Dec 12, 2025

  $CLNN Negative reaction across key levels.

  Sell

• MarketSavage

  Dec 12, 2025

  $CLNN Clene seems to be running on empty; good luck with that.

  Sell

• OptionCipher

  Dec 12, 2025

  $CLNN Momentum indicators in freefall.

  Sell

• BearWithMe

  Dec 12, 2025

  $CLNN Not a friendly chart for bulls.

  Sell

• CryptoCobra

  Dec 12, 2025

  $CLNN Bulls taking full control.

  Buy

• BearMarketSurvivor

  Dec 12, 2025

  $CLNN Buyers not backing down.

  Buy

• TheGainReaper

  Dec 11, 2025

  $CLNN Struggling to find its footing in a crowded field.

  Sell

• YieldVector

  Dec 11, 2025

  $CLNN Market confidence extremely low.

  Sell

• ShortSniper

  Dec 11, 2025

  $CLNN Accumulation phase looks nearly complete.

  Buy

• EarningsEcho

  Dec 11, 2025

  $CLNN If this stock were a movie, it'd definitely be a thriller – keeping us on the edge of our seats!

  Buy

• TradeNinja

  Dec 11, 2025

  $CLNN Bullish breakout imminent.

  Buy

• HedgeKnight

  Dec 11, 2025

  $CLNN Market showing strong bearish bias.

  Sell

• TrendStalker

  Dec 11, 2025

  $CLNN Long bias makes sense here.

  Buy

• GainSurge

  Dec 11, 2025

  $CLNN With breakthroughs on the horizon, but so many hurdles, will this company crack under pressure or emerge victorious?

  Buy

• FinTechNomad

  Dec 10, 2025

  $CLNN The future seems clouded for this player, with murky waters ahead. Investors are on edge, questioning if the innovations will be enough to pull them out of the current storm.

  Sell

• DiamondHands

  Dec 10, 2025

  $CLNN This one’s like that quiet kid in class—you might overlook them, but they could surprisingly ace the pop quiz!

  Buy

• OptionShadow

  Dec 10, 2025

  $CLNN The company's approach to addressing neurological diseases with groundbreaking technologies shows promise. Their research initiatives could pave the way for impactful solutions in a competitive healthcare landscape.

  Buy

• BuyLowBro

  Dec 10, 2025

  $CLNN This company is like the caffeine boost we all need to get through Monday mornings. Wake up and smell the innovation!

  Buy

• TradeProtocol

  Dec 10, 2025

  $CLNN If science were a rock concert, this company would be headlining. Innovative tunes that might just change the world!

  Buy

• FiscalBinary

  Dec 9, 2025

  $CLNN As biotech innovation accelerates, this company is under intense pressure to deliver groundbreaking results. The clock is ticking, and every breakthrough could be a race against time!

  Buy

• RiskAssassin

  Dec 9, 2025

  $CLNN In the world of biotech innovation, each trial is a high-stakes showdown! The suspense is palpable, and the potential for life-changing success has everyone on edge!

  Buy

• BuyTheDipBro

  Dec 9, 2025

  $CLNN It's a wild ride, but signs show it could take off.

  Buy

• BearishBoi

  Dec 9, 2025

  $CLNN Upside target achievable soon.

  Buy

• ChartCrusher

  Dec 9, 2025

  $CLNN You'd get better results playing darts blindfolded.

  Sell

• ManiaBroker

  Dec 9, 2025

  $CLNN Price action extremely fragile.

  Sell

• QuantSpecter

  Dec 9, 2025

  $CLNN Upside pressure dominating.

  Buy

• BullBrawler

  Dec 9, 2025

  $CLNN Trying hard, but still invisible in the market.

  Sell

• OptionNomad

  Dec 8, 2025

  $CLNN The race for breakthrough therapies is intense, and while potential looms large, the stakes are higher than ever. Each passing day adds to the tension for investors watching the clock!

  Sell

• QuantAssault

  Dec 8, 2025

  $CLNN Picture a science fair project gone right. This company's results could be the winning experiment or that one you forget to turn in.

  Sell

• BullRunBoi

  Dec 7, 2025

  $CLNN Watch out, they’re heating up, could be a game changer!

  Buy

• CandleBinary

  Dec 7, 2025

  $CLNN This company is making strides in the biotech arena, emphasizing innovative solutions that align with evolving healthcare needs. Its focus on clinical advancements and patient outcomes suggests a promising future ahead.

  Buy

• YieldSlasher

  Dec 7, 2025

  $CLNN New tech? More like another tech flop waiting to happen.

  Sell

• FUDCrusher

  Dec 7, 2025

  $CLNN Got that fresh vibe, lookin' to shake up the game, keep an eye out!

  Buy

• OptionShadow

  Dec 7, 2025

  $CLNN This organization is pioneering advancements in therapeutic solutions, indicating a commitment to improving patient outcomes through innovative research.

  Buy

• StonkRider

  Dec 6, 2025

  $CLNN With its unique approach to addressing unmet medical needs, this firm's pipeline holds promising potential. Its focus on innovative therapies could position it at the forefront of the healthcare industry.

  Buy

• BearishBoi

  Dec 6, 2025

  $CLNN Investing here is like joining a secret club where everyone gets cool gadgets and maybe a cake!

  Buy

• TheTradingVerse

  Dec 5, 2025

  $CLNN This company is making significant strides in the biopharmaceutical space with its innovative approach to treating serious diseases. Its commitment to research and development sets it apart as a key player poised for growth.

  Buy

• FiscalFrost

  Dec 5, 2025

  $CLNN This company is poised to make significant strides in the biotech sector, showcasing innovative approaches to treating conditions that have long needed effective solutions. Their unique technology platform could position them favorably in a competitive marketplace.

  Buy

• PnLReaper

  Dec 5, 2025

  $CLNN With a pioneering approach to cell disease treatments, this organization is carving out a niche in therapeutic solutions. Their ongoing research efforts indicate a promising outlook for both clinical results and market acceptance.

  Buy

• ShortSurge

  Dec 4, 2025

  $CLNN Charts giving more red than green.

  Sell

• ChartNomad

  Dec 4, 2025

  $CLNN Market participants showing confidence.

  Buy

• WallStreetBandit

  Dec 4, 2025

  $CLNN Very poor structure forming.

  Sell

• WallStreetHex

  Dec 4, 2025

  $CLNN Long opportunities everywhere.

  Buy

• TickerFlux

  Dec 4, 2025

  $CLNN Price action extremely lopsided.

  Sell

• StonkDestroyer

  Dec 4, 2025

  $CLNN Too many red flags in chart.

  Sell

• OptionNomad

  Dec 4, 2025

  $CLNN With regulatory hurdles at every turn, navigating the biotech maze feels like a high-stakes game. The pressure to deliver results can be overwhelming, and a single delay could spell disaster!

  Sell

• OptionMatrix

  Dec 3, 2025

  $CLNN As a biotechnology firm, this company is exploring transformative treatments that have the potential to reshape patient care. Their pipeline holds promise, but the volatile nature of the sector warrants cautious optimism.

  Sell